[1]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100-102.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):100-102.[doi:10.3969/j.issn.1006-1959.2018.21.027]
点击复制

胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年21期
页码:
100-102
栏目:
临床研究
出版日期:
2018-11-01

文章信息/Info

Title:
Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer
文章编号:
1006-1959（2018）21-0100-03
作者:
徐闻霞; 陆红艳; 黄 斌
东南大学附属江阴市人民医院胸外科，江苏 江阴 214400
Author(s):
XU Wen-xia; LU Hong-yan; HUANG Bin
Department of Thoracic Surgery,Jiangyin People's Hospital Affiliated to Southeast University, Jiangyin 214400,Jiangsu,China
关键词:
非小细胞肺癌; 肺叶切除术; 肺段切除术; 胸腔镜
Keywords:
Non-small cell lung cancer; Lobectomy; Segmentectomy; Thoracoscopic
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2018.21.027
文献标志码:
A
摘要:
目的 比较胸腔镜肺叶切除和肺段切除在ⅠA期非小细胞肺癌患者中的治疗效果。方法 回顾性分析2012年5月~2014年5月在我院行胸腔镜手术的76例ⅠA期NSCLC患者资料，按手术方式分为两组，观察组50例行肺叶切除术，对照组26例行肺段切除术。比较两组患者的手术时间、术中出血量、留置引流管时间、住院天数、并发症发生率、随访3年后复发率及死亡率。结果 观察组手术时间为（118.26±30.76）min，短于对照组的（155.51±21.91）min，差异具有统计学意义（P＜0.05）。两组患者术中出血量、留置引流管时间、住院天数、并发症发生率、随访3年后复发率和死亡率比较，差异无统计学意义（P＞0.05）。结论 ⅠA期NSCLC患者中肺段切除和肺叶切除治疗效果相似，而且肺段切除术能够保留更多的肺功能，有利于患者恢复。
Abstract:
Objective To compare the therapeutic effects of thoracoscopic lobectomy and segmentectomy in patients with stage IA non-small cell lung cancer. Methods A retrospective analysis of 76 patients with stage IA NSCLC who underwent thoracoscopic surgery from May 2012 to May 2014 was divided into two groups according to the operation. 50 patients underwent lobectomy in the observation group and 26 patients in the control group underwent segmental resection. The operation time, intraoperative blood loss, indwelling drainage tube time, length of hospital stay, complication rate, recurrence rate and mortality after 3 years of follow-up were compared between the two groups. Results The operation time of the observation group was (118.26±30.76) min, which was shorter than that of the control group (155.51±21.91) min,the difference was statistically significant (P<0.05). There were no significant differences in intraoperative blood loss, indwelling drainage time, length of hospital stay, complication rate, and recurrence rate and mortality after 3 years of follow-up between the two groups (P>0.05). Conclusion The treatment of segmental resection and lobectomy in patients with stage IA NSCLC is similar,and segmentectomy can preserve more lung function and facilitate recovery.

参考文献/References:

[1]吴朝晖,刘玳瑄,刘与友,等.全胸腔镜下肺叶切除术治疗早期非小细胞肺癌的临床观察[J].中国肿瘤临床与康复,2013,20(11):1226-1229. [2]蒋伟,奚俊杰,汪灏,等.全胸腔镜肺叶切除术治疗临床早期非小细胞肺癌的疗效评价[J].中国胸心血管外科临床杂志,2012,19(2):120-124. [3]连爱民,方勇.胸腔镜下亚肺叶切除与肺叶切除治疗T1期非小细胞肺癌的效果比较[J].安徽医学,2017,38(12):1588-1591. [4]史学良,罗杰,方秦模,等.胸腔镜亚肺叶切除术治疗肺部疾病的临床分析[J].中国老年学杂志,2015,35(13):3675-3676. [5]吴颖猛,黄伟钊,姜海明.胸腔镜下亚肺叶切除及纵隔淋巴结采样治疗早期非小细胞肺癌[J].广东医学,2013,34(8):1203-1204. [6]庞景灼,巫国勇,叶敏,等.胸腔镜肺段切除和肺叶切除在治疗早期非小细胞肺癌近期疗效的对比[J].中山大学学报(医学科学版),2015,36(4):585-589. [7]赵纯,曹隆想,张翀,等.胸腔镜下肺段切除术与肺叶切除术治疗肺癌的近期疗效评估[J].华中科技大学学报(医学版),2015,44(02):213-216,222. [8]Nakamura H,Taniguehi Y,Miwa K,et al.Comparison of the surgical outcomes of thoracoscopic lobectomy,segmentectomy,and wedgeresection for clinical stage Ⅰ non-small cell lung cancer[J].Thorac Cardiovase Surg,2011,59(3):137-141. [9]张小龙,刘伦旭.电视胸腔镜肺段切除术治疗早期非小细胞肺癌的研究进展[J].中国胸心血管外科临床杂志,2012,19(2):177-180.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]唐 佳,易明亮.肺切除术后持续咳嗽的研究进展[J].医学信息,2022,35(09):50.[doi:10.3969/j.issn.1006-1959.2022.09.012]
　TANG Jia,YI Ming-liang.Research Progress of Cough After Pulmonary Resection[J].Journal of Medical Information,2022,35(21):50.[doi:10.3969/j.issn.1006-1959.2022.09.012]
[3]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[4]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(21):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[5]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(21):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[6]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(21):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[7]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(21):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(21):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(21):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(21):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 2018-11-20